MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partners continue to market and develop breakthrough biotechnology innovations, the healthcare applications for 3D printing tech seemingly increase by the day. Researchers all across the globe are now printing everything from knee joints to heart valves and even kidney tissue, changing lives with custom creations.
But even these startling achievements are only the tip of the iceberg of the 3D bioprinting advancements to come, says RBCC CEO Kimberly Palmer.
“3D bioprinting is the first practical step toward true, regenerative medicine,” Palmer said. “It is the future of healthcare.”
Indeed, many experts agree with Palmer that 3D bioprinting is the future of healthcare—the very near future. In 2013, there was a $1.2 billion market for 3D printing in healthcare. By 2018, that figure will increase to more than $4 billion, according to a recent study by Visiongain.
In order to capture a piece of that extraordinary growth, RBCC and joint venture partner Nano3D Biosciences (n3D) are marketing and developing the BiO Assay, the world’s first magnetic 3D bioprinting system designed for rapid, high-volume drug screening.
The automated toxicity assay uses biocompatible magnetic nanoparticles to magnetize and print cells into 3D structures much faster and more affordably than competing bioprinting technology currently on the market, allowing drug makers to determine whether a compound will adversely react to human tissues and cut off pricey research if it’s headed for a dead end. Cutting-edge research utilizing the BiO Assay has been published in peer-reviewed journals such as Nature Nanotechnology, Nature Protocols, Tissue Engineering and Nature Reviews Cancer.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations such as the BiO Assay to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.